EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$10.33 USD
+0.42 (4.24%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $10.33 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EYPT 10.33 +0.42(4.24%)
Will EYPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EYPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EYPT
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
EYPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
Other News for EYPT
EyePoint Pharmaceuticals Earns ‘Outperform’ Rating on Promising Duravyu Data and Strategic FDA Alignment
TD Cowen Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Results
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
EyePoint announces developments on DURAVYU